Photo credit: phys.org
Innovative Therapy for Idiopathic Pulmonary Fibrosis: A New Approach Using Engineered Stem Cells
Researchers at the Ningbo Institute of Materials Technology and Engineering (NIMTE) under the auspices of the Chinese Academy of Sciences (CAS) have pioneered a groundbreaking method for treating idiopathic pulmonary fibrosis (IPF) through the use of engineered mesenchymal stem cells (MSCs). Their findings, detailed in a recent study published in Science Advances, could significantly boost the effectiveness of IPF therapies while allowing for real-time monitoring of treatment progress.
Understanding Idiopathic Pulmonary Fibrosis
IPF is a severe interstitial lung disease characterized by progressive lung scarring, leading to substantial mortality rates and a serious impact on health. Traditional treatments like oxygen therapy and lung transplants have provided some relief, yet researchers are increasingly focused on MSCs as a potential therapeutic alternative due to their favorable safety profile and remarkable regenerative capabilities.
Despite their promise, the clinical use of MSCs has faced challenges, particularly low survival rates post-transplantation and limited therapeutic efficacy. These limitations have hindered the broader application of MSC therapies in treating IPF.
Trimetallic Nanocarriers: A Game-Changer
In response to these challenges, the NIMTE team, led by Professors Wu Aiguo and Li Juan, developed AuPtCoPS trimetallic-based nanocarriers (TBNCs) using protamine sulfate. These innovative nanocarriers demonstrate notable enzyme-like activity, high capacity for loading therapeutic genes, and excellent computed tomography (CT) imaging capabilities.
The unique properties of the TBNCs promote the effective delivery of therapeutic genes to the lungs, targeting and neutralizing reactive oxygen species (ROS) associated with fibrosis. Additionally, the TBNCs are engineered to secrete hepatocyte growth factor (HGF) directly at affected sites, thereby enhancing the antioxidative stress response and antifibrotic effects of the MSCs. This advancement has successfully extended the in vivo survival of transplanted MSCs from approximately seven days to an impressive 14 days.
Real-Time Monitoring of Therapy
Another remarkable aspect of this research is the ability of TBNCs to serve as contrast agents for CT imaging, enabling continuous tracking of the MSCs throughout the treatment process. This capability allows for the real-time visualization of the therapeutic impact on IPF, offering valuable insights into the dynamics of the treatment’s effectiveness.
A Bright Future for Regenerative Medicine
The results from this study provide a substantial advancement in engineered MSC-based therapy for IPF and open the door to broader applications in regenerative medicine. As researchers look to the future, the prospect of developing high-performance MSCs for large-scale clinical applications seems increasingly viable.
Further Reading: Hongying Bao et al., “Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo,” Science Advances (2024). DOI: 10.1126/sciadv.adq0703
Citation: Trimetallic-based nanocarriers method shows promise for visualized idiopathic pulmonary fibrosis therapy (2024, September 16) retrieved 16 September 2024 from Phys.org.
Source
phys.org